Efficacy and Safety of Additional S-1 Chemotherapy to S-1 plus Oxaliplatin Regimen Chemotherapy for Stage III Gastric Carcinoma after Radical Resection.
Sign Up to like & getrecommendations! Published in 2021 at "Cancer investigation"
DOI: 10.1080/07357907.2021.1988961
Abstract: OBJECTIVE To investigate the efficacy and safety of additional S-1 chemotherapy to S-1 plus oxaliplatin (SOX) regimen chemotherapy for Stage III gastric carcinoma (GC) after radical resection. PATIENTS AND METHODS A total of 161 patients… read more here.
Keywords: chemotherapy; stage iii; safety; additional chemotherapy ... See more keywords
Continuation of Pembrolizumab with Additional Chemotherapy after Progression with PD-1/PD-L1 Inhibitor Monotherapy in Patients with Advanced NSCLC: A Randomized, Placebo-Controlled Phase II Study
Sign Up to like & getrecommendations! Published in 2022 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-21-3646
Abstract: Abstract Purpose: Although programmed cell death 1 (PD-1) or programmed cell death ligand 1 (PD-L1) inhibitors have shown survival benefits in patients with non–small cell lung cancer (NSCLC), most patients progress. This study evaluated whether… read more here.
Keywords: pembrolizumab additional; additional chemotherapy; inhibitor; placebo ... See more keywords